Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Checkpoint Therapeutics Inc CKPT

Healthcare Biotechnology
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber... see more

Recent & Breaking News (NDAQ:CKPT)

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

GlobeNewswire 10 days ago

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

GlobeNewswire September 16, 2024

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire August 13, 2024

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

GlobeNewswire August 12, 2024

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

GlobeNewswire July 25, 2024

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

GlobeNewswire July 15, 2024

Lifshitz Law PLLC Announces Investigations of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Shoals Technologies Group, Inc. (NASDAQ:SHLS), Live Nation Entertainment (NYSE:LYV), and The Chemours Company (NYSE:CC)

Accesswire July 12, 2024

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire July 2, 2024

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

GlobeNewswire July 2, 2024

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

GlobeNewswire June 24, 2024

Lifshitz Law PLLC Announces Investigations of The Children's Place, Inc. (NASDAQ: PLCE), Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), Fox Factory Holding Corp. (NASDAQ: FOXF), and Nextdoor Holdings, Inc. (NYSE: KIND)

Accesswire June 8, 2024

Lifshitz Law PLLC Announces Investigations of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), Fox Factory Holding Corp. (NASDAQ: FOXF), Snowflake Inc. (NYSE: SNOW), and Nextdoor Holdings, Inc. (NYSE: KIND)

Accesswire June 5, 2024

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile June 4, 2024

CKPT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire June 4, 2024

CKPT DEADLINE TODAY: TOP RANKED ROSEN LAW FIRM Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT

Newsfile June 4, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

PR Newswire June 4, 2024

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)

Business Wire June 3, 2024

CKPT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire June 3, 2024

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile June 3, 2024